Zubeen Shroff

Managing Director

Galen Partners

Joined: 1997

Office Phone:

(203) 653-6400

Direct Phone:

(203) 653-6430


  Pro - Try 1 Week Free
 

    and access,

  •     75K PE/M&A Contacts
  •     +
  •     4.5K PE Firms
  •     3.6K M&A Advisors
  •     193K Transactions
  •     197K Companies

  •     Market Services
  •     Build Lists
  •     Research Sectors
  •     Uncover Opportunities

Bio

Mr. Shroff is a Managing Director of Galen Partners, a leading healthcare growth equity investment firm founded in 1990. With over 30 years of experience in building healthcare companies, Mr. Shroff has acquired deep expertise, and demonstrated strong leadership in working with entrepreneurs to maximize shareholder value in the following areas: specialty pharmaceuticals, medical imaging, therapeutic devices, diagnostics, capital equipment, specialty supplies distribution, consumer driven healthcare, insurance & payor services, home care based solutions and technology enabled services. Successful Galen portfolio companies in which Mr. Shroff played a key leadership role include: Aperio Digital Pathology, Cambrooke Therapeutics, Dow Pharma Sciences, Encore Medical, International Medical Group, JDS Pharmaceuticals, Lumenos, MiniMed, National Rehab Equipment, Nautilus Pharmaceuticals, Quotient Biodiagnostics, SMP Pharmacy Solutions, and Tactile Medical Systems. Prior to joining Galen in 1997, Mr. Shroff was a Principal at The Wilkerson Group (sold to IBM), a leading medical products management consulting firm, with a client base including pharmaceutical, diagnostic, device and biotech companies, as well as a few select venture capital firms. He played a major role in developing several of The Wilkerson Group’s practice areas, including outcomes research, strategy formulation, and disease management initiatives. Mr. Shroff started his career at Schering-Plough Pharmaceuticals, where he directed marketing, sales, and Phase IV clinical development for the company’s high growth biotech business in France and was responsible for the launch of alpha-Interferon in several new indications. Mr. Shroff serves as an advisor to several not-for-profit institutions. He is Chairman for WMC Health, the $2.5 Billion healthcare system serving Hudson Valley New York residents. He also serves on the Boston University School for Public Health Dean’s Advisory Board. In addition, Mr. Shroff is a Fellow of the NY Academy of Medicine. He is a frequent speaker on healthcare market trends, winning medical product and service business models, and the private equity investment climate. Mr. Shroff earned an M.B.A. from the Wharton School and a B.A. in Biological Science from Boston University.

Education

Boston University , Massachusetts,
1 of 37

The Wharton School of the University of Pennsylvania , Pennsylvania,
1 of 523

Work History

Wilkerson Corp.